Sequential treatment including high-dose chemotherapy with peripheral blood stem cell support in patients with high-risk stage II-III breast cancer: Outpatient administration in community cancer centers

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 21, Issue 5, 1998, Pages 523-531

  Schwartzberg, Lee S ^a   Birch, Robert ^a   West, William H ^a   Tauer, Kurt W ^a   Wittlin, Frederick ^a   Leff, Richard ^a   Campos, Luis ^a   Rymer, William ^a   Carter, Peter ^a   Mangum, Michael ^a   Greco, F Anthony ^a   Hainsworth, John ^a   Raefsky, Eric ^a   Blanco, Rafael ^a   Buckner, C Dean ^a,b   Weaver, Charles H ^a  

^a Response Oncology Inc   (United States)

^b Response Oncology Inc   (United States)

Author keywords

High dose therapy as adjuvant therapy

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN RECEPTOR; ETOPOSIDE; FLUOROURACIL; METHOTREXATE; PROGESTERONE RECEPTOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RISK; CLINICAL TRIAL; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OUTPATIENT; PERIPHERAL BLOOD STEM CELL; PHASE 2 CLINICAL TRIAL; RECEPTOR DENSITY;

ADULT; AMBULATORY CARE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEASIBILITY STUDIES; FEMALE; FILGRASTIM; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MIDDLE AGED; NEOPLASM STAGING; SURVIVAL ANALYSIS;

EID: 0031724153     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199810000-00022     Document Type: Article

References (39)

1. Early Breast Cancer Trialists Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 1992;339:1-15,71-85.
2. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph nose status and survival in 24,740 breast cancer cases. Cancer 1989;63:181-7.
3. Gröhn P, Heinonen E, Klefström P, et al. Adjuvant postoperative radiotherapy, chemotherapy and immunotherapy in stage III breast cancer. Cancer 1984;54:670-4.
4. Peters WP, Ross M, Vredenburgh JJ, et al. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 1993;11:1132-43.
5. Jones RB, Holland JF, Bhardwaj S, et al. A phase I-II study of intensive-dose adriamycin for advanced breast cancer. J Clin Oncol 1987;5:172-7.
6. Abeloff MD, Beveridge RA, Donehower RC, et al. Sixteen-week dose-intense chemotherapy in the adjuvant treatment of breast cancer. J Natl Cancer Inst 1990;82:570-4.
7. Bonadonna G, Valagussa P. Dose-intense adjuvant treatment of high-risk breast cancer. J Natl Cancer Inst 1990;82:53-4.
8. Wood WC, Budman DR, Korzun AH, et al. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 1994;330:1253-9.
9. Peters WP, Shpall EJ, Jones RB, et al. High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol 1988;6:1368-76.
10. Antman KH. Dose-intensive therapy in breast cancer. In: Armitage JO, Antman KH, eds. High-dose cancer therapy (pharmacology, hematopoietins, stem cells). Baltimore: Williams & Wilkins, 1992;701-17.
11. Weaver C, Birch R, Schwartzberg L, et al. High-dose chemotherapy and autologous stem cell transplantation for breast cancer. In: Buckner CD, Clift R, eds. Technical and biological components of marrow transplantation. Boston: Kluwer Academic Publishers, 1995;59-85.
12. Ayash LJ, Wheeler C, Fairclough D, et al. Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast cancer. J Clin Oncol 1995;13:2043-9.
13. Bezwoda WR, Seymour L, Dansey RD. High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. J Clin Oncol 1995;13:2483-9.
14. Weaver CH, West WH, Schwartzberg LS, et al. Induction, mobilization of peripheral blood stem cells (PBSC), high-dose chemotherapy and PBSC infusion in patients with untreated stage IV breast cancer: outcomes by intent to treat analyses. Bone Marrow Transplant 1997;19:661-70.
15. de Graaf H, Willemse P, de Vries E, et al. Intensive chemotherapy with autologous bone marrow transfusion as primary treatment in women with breast cancer and more than five involved axillary lymph nodes. Eur J Cancer 1997;30A:150-3.
16. Gianni A, Siena S, Bregni M, et al. Efficacy, toxicity and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: five-year results. J Clin Oncol 1997;15:2312-21.
17. Somlo G, Doroshow J, Forman S, et al. High-dose chemotherapy and stem-cell rescue in the treatment of high-risk breast cancer: prognostic indicators of progression-free and overall survival. J Clin Oncol 1997;15:2882-93.
18. Antman K, Rowlings P, Vaughan W. et al. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol 1997;15: 1870-9.
19. American Joint Committee on Cancer. Manual for staging of cancer. 3rd ed. Philadelphia: JB Lippincott, 1988.
20. The American Society of Clinical Oncology and American Society of Hematology recommended criteria for the performance of bone marrow transplantation. J Clin Oncol 1990;8:563-4.
21. Schwartzberg L, Birch R, Hazelton B, et al. Peripheral blood stem cell mobilization by chemotherapy with and without recombinant human granulocyte colony-stimulating factor. J Hematother 1992;1:317-27.
22. Weaver CH, Schwartzberg LS, Hainsworth J, et al. Treatment related mortality in 1,000 consecutive patients receiving high-dose chemotherapy and peripheral blood progenitor cell transplantation in community cancer centers. Bone Marrow Transplant 1997;19:671-8.
23. Weaver CH, Hazelton B, Birch R, et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995; 86:3961-9.
24. Romestaing P, Lehingue Y, Carrie C, et al. Role of a 10-gy boost in the conservative treatment of early breast cancer: results of a randomized clinical trial in Lyon, France. J Clin Oncol 1997;15:963-8.
25. Green S, Weiss GR. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 1992;10:239-53.
26. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
27. Peto R, Peto J. Asymptotically efficient rank invariant test procedures. Journal of the Royal Statistical Society Series A 1972;135:185-98.
28. Cox DR. Regression models and life-tables. Journal of the Royal Statistical Society Series B 1972;34:187-202.
29. Weaver CH, Schwartzberg LS, Li W, et al. High-dose chemotherapy and autologous peripheral blood progenitor cell transplant for the treatment of Hodgkin's disease. Bone Marrow Transplant 1996;17:715-21.
30. Weaver CH, Schwartzberg LS, Zhen B, et al. High-dose chemotherapy and peripheral blood stem cell infusion in patients with non-Hodgkin's lymphoma: results of outpatient treatment in community cancer centers. Bone Marrow Transplant 1997; 20:753-60.
31. Weaver CH, Greco FA, Hainsworth J. et al. A phase I-II study of high-dose melphalan, mitoxantrone and carboplatin with peripheral blood stem cell support in patients with advanced ovarian or breast carcinoma. Bone Marrow Transplant 1997;20:847-53.
32. Schiffman KS, Bensinger WI, Appelbaum FR, et al. Phase II study of high-dose busulfan, melphalan and thiotepa with autologous peripheral blood stem cell support in patients with malignant disease. Bone Marrow Transplant 1996;17:943-50.
33. Schiffman K, Buckner C, Maloney D, et al. High-dose busulphan, melphalan and thiotepa followed by autologous peripheral blood stem cell transplantation in patients with aggressive lymphoma or relapsed Hodgkin's disease. Biol Blood Marrow Transplant 1997;3:261-6.
34. Bensinger WI, Schiffman KS, Holmberg L, et al. High-dose busulfan, melphalan, thiotepa and peripheral blood stem cell infusion for the treatment of metastatic cancer. Bone Marrow Transplant 1997;19:1183-9.
35. Jones SE, Moon TE, Bonadonna G, et al. Comparison of different trials of adjuvant chemotherapy in stage II breast cancer using a natural history data base. Am J Clin Oncol 1987;10:387-95.
36. Buzzoni R, Bonadonna G, Vologussa P, et al. Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes. J Clin Oncol 1991;9:2134-40.
37. Buzdar AU, Kau SW, Hortobagyi GN, et al. Clinical course of patients with breast cancer with ten or more positive nodes who were treated with doxorubicin-containing adjuvant therapy. Cancer 1992;69:448-52.
38. Fisher B, Redmond C, Brown A, et al. Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer. J Clin Oncol 1983;1:227-41.
39. Schwartzberg L, Birch R, Weaver C, et al. Neoadjuvant chemotherapy with or without paclitaxel and high-dose chemotherapy (HDC) with peripheral blood progenitor cell (PBPC) support for locally advanced breast cancer (LABC) [Abstract]. Proceedings of the American Society of Clinical Oncology 1996;15:124.